Pontifax Venture Capital β Full Portfolio
63 tracked investments Β· listed companies and verified rows first
A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders.
BiotechHealthtechNew York, US
Zachary Prensky(Executive Officer, Director)Lauren Stipp(Executive Officer)Mark Panoff(Executive Officer)
BoardEdmund Sullivan(Director)Vincent Grattan(Director)
Board seatRan NussbaumΒ· per SEC Form D
Co-investorsTarnagulla VenturesVida VenturesTCG Crossover
Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.
BiotechHealthtechMenlo Park, US
Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)
BoardJonathan Silverstein(Director)inCarl Gordon(Director)inFlorent Gros(Director)Erez Chimovits(Director)in
Co-investorsForesite CapitalOrbiMedQuan CapitalaMoonNovartis Venture Fund
Check-Cap Ltd.
AI & Machine LearningBiotechDeep TechRoboticsIsfiya
Mary Jo Gorman(Director)Lior Torem(Executive Officer)Yoav Kimchy(Executive Officer)Yuval Yanai(Director)Alex Ovadia(Executive Officer)Walter Robb(Director)
Co-investorsProsper Startup Accelerator
Biotechnology company developing orally available therapies for chronic inflammatory and autoimmune diseases.
BiotechNew York, US
Andreas Muehler(Executive Officer)inDaniel Vitt(Executive Officer, Director)inJASON TARDIO(Executive Officer)GLENN WHALEY(Executive Officer)INDERPAL SINGH(Executive Officer)Patrick Walsh(Executive Officer)
Co-investorsBayern Kapitalbmp VenturesFund+Omega Funds
Mereo BioPharma is a biopharmaceutical company that develops novel therapies for rare diseases with limited or no treatment options, focusing on lead programs in osteogenesis imperfecta (OI) and Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD).
BiotechLondon
John Richard(Head of Corporate Development and Co-Founder)Dr. Denise Scots-Knight(Chief Executive Officer and Co-Founder)Charles Sermon(General Counsel and Co-Founder)Richard Jones(Chief Financial Officer)Jill Henrich(Senior Vice President)
BoardDr. Deepa Pakianathan(Non-Executive Director)
Co-investorsVivo Capital
BiotechPrinceton, US
Richard C. Straube, MD MSc(Executive Officer)Karen Krumeich(Executive Officer)Oreola Donini, PhD(Executive Officer)Christopher J. Schaber, PhD(Executive Officer, Director)Adam T. Rumage(Executive Officer)R. Christopher Cavalli, PhD(Executive Officer)
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Board seatTomer KarivΒ· per SEC Form D
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesMass General Brigham Ventures+8 more
Waltham, US
Board seatTomer KarivΒ· per SEC Form D
Co-investorsRemiges Ventures, Inc.
UroGen is a biopharmaceutical company developing and commercializing treatments for urological cancers, including FDA-approved therapies such as JELMYTO and ZUSDURI built on its RTGel technology.
BiotechHealthtechPrinceton, US
Elizabeth Barrett(Executive Officer, Director)Mark Schoenberg, M.D.(Executive Officer)Jason Smith(Executive Officer)Arie Belldegrun, M.D.(Director)Dan Wildman(Director)Don Kim(Executive Officer)
Board seatRan NussbaumΒ· per SEC Form D
Co-investorsAisling CapitalMonograph Capital Partners
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical Devices
Co-investorsVida VenturesHealthCapJeito CapitalNovo HoldingsOrbiMedRA Capital+2 more
Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that use approved cancer drugs as payloads combined with optimized conjugation design to overcome resistance in precision oncology.
BiotechHealthtechMedical Devices
Jack Elands(Founder & CEO)inXavier Preville(Co-founder, VP & Head of Research & Preclinical Development)inJan H.M. Schellens(Chief Medical Officer)inThierry Menguy(VP & Head of CMC Operations)inJaime Arango(Chief Financial Officer)inPaul Jackson(Chief Operating Officer)in
Co-investorsaMoonRA CapitalBpifranceAndera PartnersAngelini VenturesKurma Partners+1 more
Agomab is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory and fibrotic diseases with high unmet medical need.
BiotechHealthtechMedical DevicesAntwerp, BE
Tim Knotnerus(Chief Executive Officer)
Co-investorsEQT Life SciencesAdBio partnersAndera PartnersAsabys PartnersCanaan PartnersV-Bio Ventures+1 more
BiotechNewton, US
Alexey Margolin(Executive Officer, Director)Louis Brenner(Executive Officer)
BoardAxel Bolte(Director)James Topper(Director)Robert Tepper(Director)inStephen Kraus(Director)
Co-investorsFrazier Life SciencesThird Rock Ventures
Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells.
BiotechBasel, CH
Thaminda(Chief Business Officer)inLaetitia Pouzol(Chief Scientific Officer)in
Co-investorsNovartis Venture FundPfizer Venture Investments
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)Tamra Adams(Executive Officer)Abel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAisling CapitalAltium CapitalAvego BioScience Capital
CathWorks makes the FFRangio System, an AI-driven technology that provides angiogram-derived fractional flow reserve and procedural modeling to help interventional cardiologists assess coronary artery disease without invasive pressure wires.
AI & Machine LearningDigital HealthMedical Devices
Co-investorsPlanven Entrepreneur VenturesTriventures
This site publishes articles about regulatory affairs for immunotherapy, covering topics such as EMA approval processes, orphan drug designation, biomarkers, clinical trials, and compliance in manufacturing.
Biotech
CytoReason builds a computational disease model that maps disease and drug mechanisms by modeling and comparing treatments and patient groups.
AI & Machine LearningBiotechHealthtech
Co-investorsAsymmetry Ventures
Eloxx Pharmaceuticals is a clinical-stage biotech developing exaluren, a ribosome-selective glycoside drug candidate that induces readthrough of premature stop codons caused by nonsense mutations to restore full-length functional proteins.
BiotechLongevity
European biopharmaceutical company advancing a nectin-4 antibody-drug conjugate for solid tumour oncology.
Co-investorsHadean VenturesRA Capital
Co-investorsKurma Partners
EyeYon Medical develops ophthalmic medical devices, including EndoArt, a synthetic corneal implant to treat corneal edema as an alternative to human tissue corneal transplants.
HardwareHealthtechMedical Devices
Co-investorsTriventures
HealthtechParis
Ronald Buggage(Executive Officer)Thierry Bordet(Executive Officer)Francine Behar Cohen(Executive Officer, Promoter)Patricia Zilliox(Executive Officer, Director, Promoter)
Co-investorsKarista
Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.
BiotechHealthtechMedical DevicesPhiladelphia, US
Co-investorsLG Technology VenturesNovartis Venture FundOrbiMedSR One Capital ManagementWindham Capital PartnersMedicxi+1 more
HealthtechMenlo Park, US
Eugene de Juan, Jr., M.D.(Executive Officer, Director)K. Angela Macfarlane(Director)
BoardWilliam J. Link, Ph.D.(Director)Warren Thaler(Director)Andy Corley(Director)Richard Lindstrom(Director)
Graviton Bioscience develops small-molecule therapies, including selective ROCK2 inhibitors, targeting fibrotic, autoimmune, and central nervous system diseases.
BiotechHealthtech
Imel Biotherapeutics is a biotech company focused on mitochondrial biology, targeting mitochondrial dysfunction implicated in aging, cellular senescence, and T cell exhaustion in the elderly population.
BiotechLongevity
Co-investorsRDiscovery
Kite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer.
BiotechHealthtechSanta Monica, US
Arie S. Belldegrun(Executive Officer, Director)Margo R. Roberts(Executive Officer)Cynthia Butitta(Executive Officer)Marc Better(Executive Officer)Rizwana Sproule(Executive Officer)
BoardJoshua A. Kazam(Director)
Co-investorsAlta Partners
LogicBio is a biotechnology company focused on research and development of treatments for rare diseases, investigating new targets, modalities, and technologies for patients and their families worldwide.
BiotechHealthtechCambridge, US
Leszek Lisowski(Executive Officer, Director)Mark A. Kay(Director)Adi Barzel(Executive Officer, Director)
BoardErez Chimovits(Director)
Co-investorsAndera PartnersArix BioscienceOrbiMed
Lutris Pharma is a clinical-stage biopharmaceutical company developing LUT014, a topical B-RAF inhibitor gel intended to reduce acneiform rash and other skin side effects caused by cancer therapies such as EGFR and RAS inhibitors.
BiotechHealthtech
Co-investorsaMoonPeregrine Ventures
Co-investorsPfizer Venture Investments
Nuvectis is a biopharmaceutical company developing oral small molecule therapies for cancer, including NXP900, an SRC Family Kinase inhibitor, and NXP800, a GCN2 activator being evaluated in solid tumors such as ovarian cancer and cholangiocarcinoma.
BiotechHealthtechFort Lee, US
James Oliviero(Director)Enrique Poradosu(Executive Officer)Matthew Kaplan(Director)Michael Carson(Executive Officer)Kenneth Hoberman(Director)Ron Bentsur(Executive Officer, Director)
OCON Therapeutics develops intrauterine drug-delivery products based on its IUB platform, including a hormone-free IUD contraceptive, an endometrial ablation device for abnormal and heavy menstrual bleeding, and a therapeutic-delivery device targeting conditions such as endometriosis and myomas.
BiotechFemTechMedical Devices
Co-investorsAstiaForeground Capital
Oxurion is a Euronext Brussels-listed Belgian company pursuing a buy-and-build strategy to build a European platform of clinical research organizations, focused on clinical data, biometrics and AI-driven research services.
AI & Machine LearningBiotechHealthtech
Co-investorsNegma Group
Co-investorsBioMedPartnersHealthCapV-Bio VenturesInkef
Co-investorsEcoR1 Capital
ProQR Therapeutics develops RNA editing therapies for patients with genetic disorders through its proprietary Axiomer RNA editing platform.
BiotechHealthtech
Co-investorsInvivo Capital PartnersSofinnova Partners
Raziel develops a proprietary fat-dissolving injectable compound (RZL-012) for non-surgical, one-time focal fat reduction addressing both aesthetic and therapeutic needs, including submental (double-chin) fat and Dercum's disease.
BiotechHealthtechMedical DevicesHod Hasharon, IL
Alon Bloomenfeld(CEO & Founder)
Lifeward (ReWalk) develops wearable exoskeletons and related products for physical rehabilitation and recovery, used in conditions such as spinal cord injury, brain injury, stroke, multiple sclerosis, and orthopedic/sports medicine.
HealthtechMedical DevicesRobotics
Co-investorsSCP Vitalife Partners
Rycarma develops a novel class of therapeutics called Rycals that target ryanodine receptors (RyRs) to correct calcium channel dysfunction in serious diseases with high unmet need.
BiotechHealthtech
Co-investorsKurma Partners
BiotechDigital HealthMedical DevicesSeattle, US
Peter A. Thompson(Executive Officer, Director)
Co-investorsEcoR1 CapitalRA CapitalUS Venture Partners
BiotechBoston, US
Gary Sternberg(Executive Officer, Director)
BoardIyona Rajkomar(Director)inWende Hutton(Director)inRichard Gaster(Director)Nanna Luneborg(Director)Daniel Curran(Director)
Co-investorsCanaan Partners
Step Pharma develops dencatistat (STP938), a first-in-class, orally bioavailable CTPS1 inhibitor in clinical development as a targeted oncology therapy for blood cancers such as lymphoma and essential thrombocythaemia as well as solid tumours including ovarian cancer.
BiotechDeep TechMedical DevicesSaint-Genis-Pouilly, FR
Co-investorsHadean VenturesKurma PartnersSunstone CapitalV-Bio Ventures
StrideBio develops gene therapies based on its STRIVE AAV capsid platform, targeting people with life-threatening diseases.
BiotechHealthtechDurham, US
Aravind Asokan(Director)Mavis Abjandje-McKenna(Director)Richard Smith(Executive Officer)Patrick Ritschel(Executive Officer, Director, Promoter)
Co-investorsHatteras Venture Partners
Sweetch provides a patient-engagement platform that delivers personalized recommendations to help people with chronic conditions adhere to their treatment programs, covering medication adherence, physical activity, nutrition, sleep, and remote patient monitoring.
AI & Machine LearningDigital HealthHealthtech
Co-investorsEntrΓ©e CapitalLionBirdTal VenturesTenmileOurCrowd
V-Wave develops the Ventura Interatrial Shunt, an hourglass-shaped percutaneous implantable device that reduces left atrial pressure by offloading volume from the left atrium to the right atrium in patients with chronic heart failure.
BiotechHealthtechMedical Devices
Co-investorsAPERTURE Venture PartnersBRM CapitalTriventures
BiotechChicago, US
Rand Sutherland(Director)James Sullivan(Executive Officer, Director)in
BoardJonathan Silverstein(Director)inBernard Davitian(Director)Uya Chuluunbaatar(Director)Mona Ashiya(Director)in
Co-investorsOrbiMed
Vanqua Bio is a biotechnology company discovering and developing novel therapies for Parkinson's disease and other neurological and neurodegenerative diseases, drawing on lysosomal biology and innate immune system science.
BiotechDeep TechHealthtechChicago, US
Jim Sullivan(CEO)Kevin Hunt(CSO)
Co-investorsAvoro Capital AdvisorsOrbiMed
VGS (Vascular Graft Solutions) develops medical technologies for coronary artery bypass surgery (CABG), including VIOLA for clampless proximal aortic anastomosis and VEST, an external support device for vein grafts.
HardwareHealthtechMedical Devices
Co-investorsBroadview VenturesGEOCTal Ventures
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.